Quantitative Blood Tests Help Diagnose Neuroscience-Related Diseases

Molecular nanotechnology is used in vitro diagnostic devices (IVDDs) for the quantitative measurement of blood parameters to evaluate the input and output of the brain through specific neuro-biomarkers.

A new, reliable portfolio of 12 quantitative blood tests will provide general practitioners and specialists clinical parameters for the diagnosis of neuroscience-related diseases or physiopathological impairments. This is accomplished by identifying abnormal readings of specific biomarkers within the blood or other biological fluids.

The blood tests are to be used for the detection, prevention, monitoring, and follow-up of the major stress-related, socioprofessional and occupational diseases. These include chronic fatigue syndrome (CFS), great anxiety (GA), panic syndrome (PS), neuropathies or fibromyalgia (FM), certain cardiovascular diseases, neurodegenerative diseases such as Alzheimer and Parkinson Diseases, as well as mental-health disorders such as depression and schizophrenia.

Developed by Neuro-Biotech Corp. (Basel, Switzerland), the diagnostic tests are noninvasive, sensitive, reliable, and produce rapid results. They will complement current clinical laboratory testing procedures.

Neuro-Biotech's expertise in clinical neurosciences applied enzymology is dedicated to the understanding of the relationship between the neurotransmitter families within the brain and their various influences on the peripheral systems involving the hypothalamopituitary adreno-sympathetic (HPAS) axis. The HPAS axis manages body mechanisms against stressful situations and maintains the homeostasis responsible for the resistance of the organism to its psycho-socio-environment through psycho-neuroimmune and endocrine systems.

Related Links:
Neuro-Biotech Corp.